Comparative study of the immune system after tooth brushing with UB-612 vaccine against new coronavirus infection

Abstract

Background: At the end of December 2019, the first cluster of coronavirus infections caused by the SARS-CoV-2 virus with an acute respiratory syndrome pattern was reported in Wuhan, China. Many vaccines are being developed around the world, one of which, is UB-612, a polypeptide construct of protein I, which has been shown to stimulate both cellular and humoral immune responses. Masu. Therefore, the study aims to investigate how it affects the immune response. Materials and Methods: This study is a randomized, active-controlled, open-label, single-center study to measure N protein following a heterologous booster dose of the approved COVID-19 vaccine UB-612 in adults. there were. N-68 participants aged 18 years and older who received their two doses of the Sinopharm vaccine were randomized. This study was conducted by Good Clinical Practices (GCP). Anti-SARS-CoV-2 was measured by enzyme-linked immunosorbent assay. N protein levels in study participants were measured before (day 1) and after (day 29) a booster dose of the homologous vaccine. Results: N protein levels in study participants before (1 day) additional administration of allogeneic vaccine Gray zone n=9 (13.2%), negative n=38 (55.8%), positive n=21 (30.9%) and addition of allogeneic vaccine Post-administration (29 days) Gray zone: n=9(13.2%), negative: n=12 (17.6%), positive: 47 (69.1%). After additional administration of the allogeneic vaccine, N protein levels increased. Conclusion: The N protein content of participants who received two doses of the Sinopharm vaccine increased compared to the N protein content after receiving a booster dose of the heterologous vaccine.